Overview

Cost-Effectiveness Study of PEG-rhG-CSF in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma

Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
0
Participant gender:
All
Summary
This is a pharmacoeconomic research to explore the cost-effectiveness of PEG-rhG-CSF and rhG-CSF in prophylactic treatment of neutropenia in lymphoma patients. It should provide more scientific basis for clinical decision-making.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Ruijin Hospital
Criteria
Inclusion Criteria:

- 18-65 years

- histologically confirmed de novo Non Hodgkin's lymphoma (except highly aggressive
lymphoma such as lymphoblastic lymphoma and Burkitt lymphoma)

- plan to be given 6-8 cycles of cyclophosphamide, doxorubicin, vincristine, and
prednisone (CHOP) ± Rituximab (R)

- KPS ≥70

- plan continuous PEG-rhG-CSF or rhG-CSF adiministration after at least 3 cycles of
treatment for neutropenia prophylactic treatment

- absolute neutrophil count≥1.5×109/L,platelet count ≥100× 109/L,hemoglobin≥90g/L,while
blood cell count≥3.0×109/L,without bleeding signs

- adquate liver and renal function as protocol discribed

- no serious cardiovascular disease as protocol discribed

- under good mental conditions and informed consented

- potential benefit for subjects based on investigators' decision

Exclusion Criteria:

- history of hematopoetic stem cell transplantationor organ transplantation

- uncontrollable infection

- allergic to study drugs or ingredients

- accepted any other investigational drug or participated another interventional study
within 30 days during screening period

- other uncontrollable conditions judged by the investigator

- breast-feeding , pregnant or plan to be pregnant during study observation period